drugset
drugset / Trial / NCT05173805

Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation

NCT05173805 ↗

Phase 1/2 Unknown 150 enrolled Shanghai YingLi Pharmaceutical Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1 / 2 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-15293 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2 dose of YL-15293 and obtain the preliminary efficacy information of patients with advanced solid tumors with KRAS mutation.

Timeline

Start
2022-01-30
Primary completion
2024-04-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject YL-15293 Unknown 100 mg Oral
Subject YL-15293 Unknown 200 mg Oral
Subject YL-15293 Unknown 400 mg Oral
Subject YL-15293 Unknown 600 mg Oral
Subject YL-15293 Unknown 800 mg Oral
Subject YL-15293 Unknown 1000 mg Oral
Subject YL-15293 Unknown 1200 mg Oral

Indications

neoplasm